Physician profile
Patsy L Howell
NPI 1609548767
$2,400.99
in general payments reported to CMS, 2019-2025
28 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.66 · 2022: $26.90 · 2023: $141 · 2024: $798 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,359.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $540.94 | 2024-2025 | |
| Daiichi Sankyo INC. | $315.51 | 2023-2025 | Enhertu, Datroway |
| Abbvie INC. | $198.62 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $159.07 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Incyte Corporation | $148.08 | 2023-2025 | Jakafi, Niktimvo, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $144.79 | 2021-2025 | Tagrisso, Calquence |
| Regeneron Healthcare Solutions, INC. | $91.15 | 2024-2025 | Libtayo |
| Janssen Biotech, INC. | $78.50 | 2024-2025 | Talvey, Darzalex, Imbruvica |
| Glaxosmithkline, LLC. | $67.33 | 2023-2024 | Zejula |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.81 | 2025 | |
| Genmab U.S., INC. | $60.62 | 2025 | Tivdak, Epkinly |
| Stemline Therapeutics INC. | $56.14 | 2024-2025 | Orserdu |
| Coherus Oncology, INC. | $49.60 | 2023-2024 | |
| Blueprint Medicines Corporation | $38.67 | 2025 | Ayvakit |
| Pfizer INC. | $36.87 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $36.31 | 2025 | |
| Pharmaessentia USA Corporation | $34.73 | 2025 | Besremi |
| Lilly USA, LLC | $34.05 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Array Biopharma INC | $33.63 | 2025 | Mektovi, Lorbrena, Xalkori |
| Pharmacosmos Therapeutics INC. | $33.22 | 2023 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $32.32 | 2023-2025 | Ninlaro |
| Novocure INC. | $28.81 | 2022-2025 | Optune Lua (Novottf-200t) |
| Sun Pharmaceutical Industries INC. | $22.63 | 2024 | |
| Astellas Pharma US INC | $22.61 | 2025 | Xtandi |
| Sobi, INC | $22.22 | 2024 | |
| Celltrion USA INC. | $17.72 | 2025 | Vegzelma |
| Aveo Pharmaceuticals, INC. | $17.49 | 2024 | |
| Tersera Therapeutics LLC | $13.55 | 2025 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patsy Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.